Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $13.3 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $13.3 million, down 71.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (down 71.99% YoY), and the FY2025 annual result was $13.8 million, up 14.62% from the prior year.
• Total Non-Current Liabilities came in at $13.3 million for Q1 2026 at Insight Molecular Diagnostics, down from $13.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $81.9 million in Q1 2022 to a low of $8.5 million in Q2 2025.
• The 5-year median for Total Non-Current Liabilities is $17.9 million (2022), against an average of $27.6 million.
• Across the five-year window, Total Non-Current Liabilities soared 464.85% in 2022 and tumbled 84.27% in 2025, its largest moves.
• Insight Molecular Diagnostics' Total Non-Current Liabilities stood at $17.9 million in 2022, then sank by 49.0% to $9.1 million in 2023, then jumped by 31.62% to $12.0 million in 2024, then climbed by 14.62% to $13.8 million in 2025, then fell by 3.29% to $13.3 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $13.3 million (Q1 2026), $13.8 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.